✦ LIBER ✦

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

✍ Scribed by Vanesa Gregorc; Giovanni Citterio; Giordano Vitali; Anna Spreafico; Paola Scifo; Anna Borri; Giovanni Donadoni; Gilda Rossoni; Angelo Corti; Federico Caligaris-Cappio; Alessandro Del Maschio; Antonio Esposito; Francesco De Cobelli; Flavio Dell’Acqua; Antonella Troysi; Paolo Bruzzi; Antonio Lambiase; Claudio Bordignon

Book ID: 116430196
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 356 KB
Volume: 46
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2009.10.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase Ib study of NGR–hTNF, a selective

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

✍ Gregorc, V; Santoro, A; Bennicelli, E; Punt, C J A; Citterio, G; Timmer-Bonte, J 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 216 KB

Factors affecting the unexpected failure

Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients

✍ Ingrid M.E. Desar; Carla M.L. van Herpen; Jack J.A. van Asten; Walter Fiedler; S 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 629 KB

Activity and safety of NGR-hTNF, a selec

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

✍ Santoro, A; Pressiani, T; Citterio, G; Rossoni, G; Donadoni, G; Pozzi, F; Rimass 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 513 KB

1228 Phase I study of NGR-hTNF, a vascul

1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours

✍ G. Citterio; F.G. De Braud; V. Gregorc; T.M. De Pas; C. Noberasco; S. Boselli; M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

6617 Phase II study of NGR-hTNF, a selec

6617 Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC)

✍ Santoro, A.; Citterio, G.; Pressiani, T.; Gregorc, V.; Rimassa, L.; De Braud, F. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB